1. Home
  2. EH vs MGNX Comparison

EH vs MGNX Comparison

Compare EH & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EHang Holdings Limited ADS

EH

EHang Holdings Limited ADS

N/A

Current Price

$2.85

Market Cap

257.9M

Sector

Industrials

ML Signal

N/A

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

N/A

Current Price

$1.99

Market Cap

262.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EH
MGNX
Founded
2014
2000
Country
China
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
257.9M
262.4M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
EH
MGNX
Price
$2.85
$1.99
Analyst Decision
Buy
Buy
Analyst Count
10
7
Target Price
$7.83
★ $8.00
AVG Volume (30 Days)
651.2K
★ 1.0M
Earning Date
11-30-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $149,500,000.00
Revenue This Year
$1.85
N/A
Revenue Next Year
$70.64
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.28
$1.32
52 Week High
$15.27
$5.08

Technical Indicators

Market Signals
Indicator
EH
MGNX
Relative Strength Index (RSI) 29.09 25.46
Support Level N/A $1.63
Resistance Level $4.27 $3.39
Average True Range (ATR) 0.27 0.18
MACD -0.07 0.00
Stochastic Oscillator 2.10 0.00

Price Performance

Historical Comparison
EH
MGNX

About EH EHang Holdings Limited ADS

EHang Holdings Ltd is an urban air mobility (UAM) technology platform company focused on autonomous aerial vehicle technology and solutions. The company provides unmanned aerial vehicle (UAV) systems and solutions for air mobility, including passenger transportation and logistics, as well as smart city management and aerial media solutions. Its EH216-S passenger-carrying pilotless eVTOL aircraft has obtained a production certificate and standard airworthiness certificate from the Civil Aviation Administration of China (CAAC).

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: